Motegrity (Prucalopride)
prucalopride
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Chronic idiopathic constipation (CIC) | Adults (both men and women) | Monotherapy | FDA Approved |
Prucalopride received FDA approval for CIC in adults in December 2018, making it the first selective 5-HT4 receptor agonist available in the United States since tegaserod was restricted. Unlike the secretagogues (linaclotide, plecanatide, lubiprostone), prucalopride is a true prokinetic agent that works by stimulating high-amplitude propagating contractions in the colon. It had been approved in Europe since 2009 (initially for women only) and the US approval extended to both sexes based on an integrated analysis of six trials. The AGA/ACG 2023 CIC guideline issued a strong recommendation for prucalopride based on moderate-certainty evidence, placing it alongside linaclotide and plecanatide as a preferred prescription option after failure of over-the-counter agents. Prucalopride does not have FDA-approved indications for IBS-C or OIC.
Chronic intestinal pseudo-obstruction: Small n-of-1 cross-over studies suggest symptom benefit in selected patients with visceral myopathy. Evidence quality: Very low.
Gastroparesis: Limited case series suggest potential prokinetic benefit; not systematically evaluated. Evidence quality: Very low.
Pediatric functional constipation: A Phase 3 pediatric trial was terminated early for futility (FDA PI). Evidence quality: Low (negative trial).
Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| CIC — adult with normal renal function | 2 mg once daily | 2 mg once daily | 2 mg/day | Take with or without food; no titration required 4 mg dose tested in trials but did not offer additional benefit |
| CIC — severe renal impairment (CrCL <30 mL/min) | 1 mg once daily | 1 mg once daily | 1 mg/day | AUC increased 2.38-fold in severe renal impairment Based on CrCL from 24-hour urine collection |
| CIC — elderly patients | 2 mg once daily (or 1 mg if CrCL <30) | Dose based on renal function | 2 mg/day | Higher exposure in elderly related to reduced renal function, not age itself No separate age-based dose adjustment; adjust for renal function |
| CIC — end-stage renal disease (ESRD) on dialysis | AVOID — PK not fully characterized in dialysis patients | Per FDA PI Section 8.6 | ||
Prucalopride is the only prescription CIC agent that is a true prokinetic — it stimulates colonic high-amplitude propagating contractions (HAPCs) rather than increasing intestinal fluid secretion. This makes it a mechanistically distinct alternative for patients who have not responded to secretagogues (linaclotide, plecanatide, lubiprostone) or who experience intolerable diarrhea or nausea with those agents. It can be taken with or without food at any time of day, and the once-daily dosing with a 24-hour half-life provides consistent around-the-clock prokinetic activity.
Pharmacology
Mechanism of Action
Prucalopride is a highly selective serotonin type 4 (5-HT4) receptor agonist with a dihydrobenzofurancarboxamide structure. It stimulates colonic peristalsis by facilitating acetylcholine release from enteric neurons, which generates high-amplitude propagating contractions that propel colonic contents toward the rectum. Importantly, prucalopride is devoid of meaningful activity at 5-HT2A, 5-HT2B, 5-HT3, motilin, or CCK-A receptors at concentrations exceeding its 5-HT4 receptor affinity by at least 150-fold. This high selectivity distinguishes it from earlier 5-HT4 agonists (cisapride, tegaserod) that were associated with serious cardiovascular adverse events due to off-target receptor interactions. In an integrated analysis of 3 dose-finding studies, prucalopride 2 mg reduced mean colonic transit time by approximately 12 hours from a baseline of 65 hours, compared to no change with placebo. At 5 times the maximum recommended dose, prucalopride does not prolong the QT interval to any clinically relevant extent.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability >90%; Tmax 2–3 h; food does not affect bioavailability | Reliable systemic absorption allows consistent prokinetic effect; no food restrictions |
| Distribution | Vss 567 L; protein binding ~30%; steady state in 3–4 days; trough 2.5 ng/mL, peak 7 ng/mL at 2 mg QD | Large volume of distribution indicates extensive tissue penetration; low protein binding means minimal displacement interactions |
| Metabolism | CYP3A4 substrate in vitro; however, parent drug comprises 92–94% of plasma radioactivity; 7 minor metabolites, most abundant (O-desmethyl prucalopride acid) is 0–1.7% of total | Metabolism is minimal; CYP3A4 inhibitors (e.g., ketoconazole) increase exposure by ~40% but this is not considered clinically significant |
| Elimination | Renal excretion is the main route: 60–65% excreted unchanged in urine, ~5% in feces; total recovery 84% urine, 13% feces; t½ ~24 h; clearance 317 mL/min | Predominantly renally cleared as parent drug (filtration + active secretion); dose reduction required in severe renal impairment; avoid in ESRD on dialysis |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Headache | 19% vs 9% placebo | Most common AE; 66% report onset within first 2 days; resolves within a few days in 65% of affected patients; d/c rate 1% |
| Abdominal pain | 16% vs 11% placebo | Includes upper/lower abdominal pain, abdominal tenderness, discomfort, and epigastric discomfort; d/c rate 1% |
| Nausea | 14% vs 7% placebo | D/c rate 2%; typically self-limiting; no food requirement like lubiprostone |
| Diarrhea | 13% vs 5% placebo | 70% onset in first week; resolves within a few days in 73%; severe in 1.8% vs 1% placebo; d/c rate 1% |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Abdominal distension | 5% vs 4% placebo | Usually self-limiting |
| Dizziness | 4% vs 2% placebo | May relate to central 5-HT4 activity; generally transient |
| Vomiting | 3% vs 2% placebo | More common in early treatment |
| Flatulence | 3% vs 2% placebo | Related to increased colonic motility |
| Fatigue | 2% vs 1% placebo | Typically transient |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Suicidal ideation and behavior | Rare (clinical trials + postmarketing); causal link not established | Within first few weeks of starting; also reported after discontinuation | Discontinue immediately if suicidal thoughts/behavior emerge; instruct patients and caregivers to report unusual mood changes; monitor for depression |
| MACE (cardiovascular death, MI, stroke) | IR 3.5/1000 patient-years (vs 5.2 placebo in double-blind trials) | Variable | Observational cohort study excluded ≥3-fold MACE risk vs PEG; no increased CV risk demonstrated; standard CV risk assessment |
| Hypersensitivity (dyspnea, rash, urticaria, facial edema) | Very rare (postmarketing) | Any time | Discontinue permanently; standard allergy management; prucalopride is contraindicated with known hypersensitivity |
The July 2025 label update added enhanced language regarding psychiatric adverse events. In clinical trials, one suicide attempt occurred 7 days after treatment ended (2 mg group); in open-label trials, two additional suicide attempts and one case of suicidal ideation were reported. Two completed suicides occurred in patients who had discontinued prucalopride at least one month prior. Postmarketing reports include depression, anxiety, insomnia, nightmares, and visual hallucinations. A causal association has not been established, but all patients should be monitored for new-onset or worsening mood disturbance. Instruct patients and caregivers to report any unusual changes in mood or behavior and to discontinue the drug immediately if such changes occur.
Drug Interactions
Prucalopride has a favorable but more nuanced drug interaction profile than the locally-acting secretagogues, because it is systemically absorbed and is a CYP3A4 substrate. However, in clinical studies, ketoconazole (a strong CYP3A4/P-gp inhibitor) only increased prucalopride exposure by approximately 40%, which was not considered clinically significant. In vitro, prucalopride does not inhibit or induce major CYP enzymes or transporters at clinically relevant concentrations. No clinically significant interactions were found with warfarin, digoxin, paroxetine, or oral contraceptives.
Monitoring
- Psychiatric StatusBaseline and ongoing
RoutineMonitor all patients for new-onset or worsening depression, suicidal ideation, self-injurious thoughts, and unusual mood or behavioral changes. Counsel patients, caregivers, and family members. Instruct patients to discontinue prucalopride immediately and contact their healthcare provider if any of these symptoms emerge. - Renal FunctionBaseline (for dose selection)
RoutineAssess CrCL before initiating therapy. Reduce to 1 mg QD if CrCL <30 mL/min. Avoid in patients with ESRD requiring dialysis. In elderly patients, adjust dose based on renal function rather than age. - Stool PatternWeeks 1–2, then as needed
RoutineHeadache and diarrhea typically onset within the first 1–2 days and resolve within a few days. Most adverse effects attenuate with continued use. If severe diarrhea occurs, ensure adequate hydration and correct any electrolyte disturbances. - Cardiovascular StatusStandard risk assessment
RoutineThe FDA-mandated MACE analysis showed no increased cardiovascular risk compared to PEG. No QT prolongation at therapeutic doses. Routine cardiac monitoring is not required beyond standard clinical assessment, but the drug is contraindicated in patients with intestinal perforation or severe inflammatory bowel conditions. - Treatment Efficacy4–12 weeks
RoutineAssess whether the patient achieves ≥3 SCBMs/week. In pooled trials, 27.8% of prucalopride-treated patients achieved this target vs 13.2% with placebo over 12 weeks. If no response after 4 weeks, reassess treatment strategy.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to prucalopride: Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been reported.
- Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus.
- Severe inflammatory conditions of the intestinal tract: Crohn’s disease, ulcerative colitis, toxic megacolon/megarectum.
Relative Contraindications (Specialist Input Recommended)
- End-stage renal disease (ESRD) requiring dialysis: Pharmacokinetics not fully characterized in this population; avoid use.
- Active psychiatric illness (depression, suicidal ideation): Given the postmarketing psychiatric safety signals, exercise caution in patients with pre-existing mood disorders.
Use with Caution
- Severe renal impairment (CrCL <30 mL/min): Dose reduction to 1 mg QD required; 2.38-fold increase in AUC.
- Pregnancy: Insufficient human data; no animal teratogenicity at doses up to 390× the recommended human dose. A pregnancy exposure registry is available (MotherToBaby: 1-877-311-8972).
- Lactation: Prucalopride is present in breast milk at a milk-to-plasma AUC ratio of 2.65:1. The estimated infant exposure is approximately 6% of the weight-adjusted maternal dose. Consider the benefits of breastfeeding against the potential risk.
In clinical trials and postmarketing experience, suicides, suicide attempts, suicidal ideation, self-injurious ideation, and new-onset or worsening depression have been reported in patients receiving prucalopride, including within the first few weeks of treatment. Although a causal association has not been established, all patients should be monitored for psychiatric symptoms. Instruct patients to discontinue the drug immediately and contact their healthcare provider if they experience unusual changes in mood or behavior or the emergence of suicidal thoughts.
Patient Counselling
Purpose of Therapy
Prucalopride works differently from other constipation medications. Instead of adding fluid to the intestine, it acts on serotonin receptors in the gut wall to stimulate the natural muscle contractions that move stool through the colon. It is taken once daily and can be taken with or without food. Most patients experience improvement in bowel frequency within the first week.
How to Take
Take one tablet once daily, with or without food, at any time of day. If you miss a dose, skip it and take the next one at your regular time. If you have kidney problems, your doctor may prescribe the lower 1 mg dose.
Sources
- MOTEGRITY (prucalopride) tablets, for oral use. Full Prescribing Information. Takeda Pharmaceuticals (originally Shire US Inc.). Revised July 2025. FDA labelPrimary source for all dosing, adverse reaction rates, contraindications, suicidality warning, and pharmacokinetic data.
- Motegrity (prucalopride) FDA Approval History. Drugs.com. Accessed April 2026. Drugs.comTimeline of FDA regulatory actions from initial approval (Dec 2018) through label updates.
- Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344–2354. DOIPivotal Phase 3 trial (Study 1) demonstrating 30.9% responder rate with 2 mg vs 12% placebo (p<0.001).
- Tack J, van Outryve M, Beyens G, et al. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut. 2009;58(3):357–365. DOIPivotal Phase 3 trial (Study 2) in laxative-refractory patients confirming efficacy of 2 mg once daily.
- Quigley EMM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation. Aliment Pharmacol Ther. 2009;29(3):315–328. DOIThird pivotal Phase 3 trial (Study 3) confirming efficacy (24% vs 12% placebo) and quality-of-life improvements.
- Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation: an integrated analysis of six randomized, controlled clinical trials. Dig Dis Sci. 2016;61(8):2357–2372. DOIPooled analysis of all 6 Phase 3/4 trials (N=2484) demonstrating 27.8% vs 13.2% responder rate and safety in both men and women.
- Yiannakou Y, Piessevaux H, Bouchoucha M, et al. A randomized, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy, safety, and tolerability of prucalopride in men with chronic constipation. Am J Gastroenterol. 2015;110(5):741–748. DOIPhase 3 trial confirming efficacy in men (37.9% vs 17.7% placebo), supporting extension of indication to both sexes.
- Chang L, Chey WD, Imdad A, et al. AGA–ACG Clinical Practice Guideline: pharmacological management of chronic idiopathic constipation. Gastroenterology. 2023;164(7):1086–1106. DOIStrong recommendation for prucalopride in CIC after OTC agent failure, based on moderate-certainty evidence.
- Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17–44. DOIACG guideline noting prucalopride’s role in CIC management; not indicated for IBS-C.
- Briejer MR, Bosmans JP, Van Daele P, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423(1):71–83. DOIKey pharmacological profiling study demonstrating high selectivity for 5-HT4 over 5-HT2B and hERG channels.
- Miner PB Jr, Camilleri M, Burton D, et al. Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study. Neurogastroenterol Motil. 2016;28(9):1341–1348. DOIMechanistic study confirming prucalopride-induced HAPCs in CIC patients, supporting the prokinetic mechanism.
- Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation — follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010;32(9):1113–1123. DOIOpen-label extension (N=1455) demonstrating sustained efficacy and tolerability for up to 18 months; GI events and headache caused discontinuation in ~5%.
- Müller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22(9):991–998. DOIDedicated elderly trial (Study 4) demonstrating safety and tolerability in patients ≥65 years; higher exposure related to renal function, not age.